Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05522881
Other study ID # T1322
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 25, 2022
Est. completion date December 30, 2029

Study information

Verified date November 2023
Source National Health Research Institutes, Taiwan
Contact Shang-Hung Chen, MD.PhD
Phone 886 (06) 7000123
Email bryanchen@nhri.edu.tw
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

We will use the next-generation sequencing (NGS) technology to identify genomic alterations of Taiwanese HPV positive and negative oropharyngeal squamous cell carcinoma (OPSCC) for novel biomarker development and the study design of potential clinical trials or translational research.


Description:

In the past decade, next-generation sequencing (NGS) technology has enabled cancer genome sequencing in screening and searching for new cancer genes in an efficient manner. This massive sequencing technique not only help to identify new altered genes for novel biomarker development, but also reveal gene alterations sensitive or resistant to specific therapies. Because the difference of genomic profiling between Taiwanese HPV positive and negative OPSCC is not clear yet, we propose this multi-center research project to address this issue. In this study, we will collect tumor tissues and clinical information from patients with OPSCC and create a platform for data storage and sharing.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date December 30, 2029
Est. primary completion date December 30, 2029
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: 1. Ages 20 and above 2. Pathological reported as squamous cell carcinoma of oropharynx (soft palate, tonsil, base of tongue, pharyngeal wall, uvula or vallecula) 3. Available p16 immunohistochemical staining status 4. Willingness to provide archival or newly obtained tumor tissues for current study proposal 5. Life expectancy more than 3 months 6. Patients fully understand the protocol with the willingness to have regular follow-up Exclusion criteria 1. Inability to cooperate by providing a complete medical history 2. No available tumor tissues for genetic testing 3. Undesirable compliance 4. Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Taiwan Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung
Taiwan Kaohsiung Veterans General Hospital Kaohsiung
Taiwan China Medical University Hospital Taichung
Taiwan Taichung Veterans General Hospital Taichung
Taiwan National Cheng Kung University Hospital Tainan
Taiwan Pei-Jen Alex Lou Taipei
Taiwan Taipei Veterans General Hospital Taipei

Sponsors (7)

Lead Sponsor Collaborator
National Health Research Institutes, Taiwan China Medical University Hospital, Kaohsiung Veterans General Hospital., National Cheng-Kung University Hospital, National Taiwan University Hospital, Taichung Veterans General Hospital, Taipei Veterans General Hospital, Taiwan

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary To enroll a total of 300 patients with OPSCC who fit the criteria of this study in the enrolled period To enroll a total of 300 patients with OPSCC who fit the criteria of this study in the enrolled period 5 years of proposed observation period
Secondary To perform next generation sequencing analysis of OPSCC tumor tissues To perform next generation sequencing analysis of OPSCC tumor tissues 5 years of proposed observation period
Secondary Collect clinical data of OPSCC To correlate with the clinical characteristics and treatment outcomes of patients with the genetic profile in Taiwan. 5 years of proposed observation period
Secondary To compare the difference of the genetic and molecular profiles among patients with HPV positive and negative OPSCC To compare the difference of the genetic and molecular profiles among patients with HPV positive and negative OPSCC 5 years of proposed observation period
Secondary To compare the difference of genetic and molecular profiles between early (stage I and II) and advanced stage (stage III and IV) of HPV positive OPSCC To compare the difference of genetic and molecular profiles between early (stage I and II) and advanced stage (stage III and IV) of HPV positive OPSCC 5 years of proposed observation period
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06174428 - Validity of Viome's Oral/Throat Cancer Test
Recruiting NCT05098119 - Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) Phase 2
Suspended NCT03952585 - De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer Phase 2/Phase 3
Terminated NCT03618134 - Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner Phase 1/Phase 2
Recruiting NCT03421470 - Docetaxel and Radiation Therapy in Treating Patients With HPV Positive Oropharynx Cancer Phase 3
Completed NCT06314711 - Ex Vivo 3D-ultrasound for Oropharyngeal Cancer N/A
Completed NCT04572100 - Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer Phase 1
Not yet recruiting NCT06055868 - People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
Recruiting NCT04222543 - Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging Phase 2
Recruiting NCT04564989 - Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
Active, not recruiting NCT04965792 - Post-treatment Surveillance in HPV+ Oropharyngeal SCC
Recruiting NCT06356272 - Oropharynx (OPX) Biomarker Trial
Active, not recruiting NCT01874171 - Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC Phase 3
Recruiting NCT05333523 - Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study. Phase 3
Completed NCT03618654 - Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma Early Phase 1
Recruiting NCT04801472 - Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) N/A
Active, not recruiting NCT03410615 - Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC Phase 2
Recruiting NCT05268614 - Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT05582590 - Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers Phase 1
Completed NCT02072148 - The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL) N/A